Inmagene Biopharma of Shanghai acquired greater China rights to a bispecific molecule aimed at Interleukin-17A (IL-17) for multiple autoimmune diseases from Sweden’s Affibody AB. ABY-035 is currently undergoing a German Phase II trial in patients with psoriasis, where it has shown clear clinical benefits and a good safety profile. Inmagene will be responsible for commercialization in Greater China and South Korea along with development activities in Asia Pacific region, excluding Japan.
Source: China Biotoday